Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the Definition of Cancer. Molecular Cancer Research. 2023;21https://doi.org/10.1158/1541-7786.MCR-23-0411

Article  PubMed  PubMed Central  Google Scholar 

Can G. Cancer basics. Medical Nursing. 2023.

Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021.https://doi.org/10.1177/20503121211034366

Article  PubMed  PubMed Central  Google Scholar 

McCune JS. Immunotherapy to Treat Cancer. Clin Pharmacol Ther. 2016.https://doi.org/10.1002/cpt.404

Article  PubMed  Google Scholar 

McCune JS. Rapid Advances in Immunotherapy to Treat Cancer. Clin Pharmacol Ther. 2018.https://doi.org/10.1002/cpt.985

Article  PubMed  Google Scholar 

Boardman DA, Levings MK. Cancer immunotherapies repurposed for use in autoimmunity. Nat Biomed Eng. 2019.https://doi.org/10.1038/s41551-019-0359-6

Article  PubMed  Google Scholar 

American Cancer Society. How immunotherapy is used to treat cancer. American Cancer Society. 2019;

Amin M, Lockhart AC. The potential role of immunotherapy to treat colorectal cancer. Expert Opin Investig Drugs. 2015.https://doi.org/10.1517/13543784.2015.985376

Article  PubMed  Google Scholar 

Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022.https://doi.org/10.1007/s11033-022-07525-8

Article  PubMed  PubMed Central  Google Scholar 

Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S. Promising approaches in cancer immunotherapy. Immunobiology. 2020. https://doi.org/10.1016/j.imbio.2019.11.010

Article  PubMed  Google Scholar 

Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology. 2022.https://doi.org/10.3390/curroncol29050247

Article  PubMed  PubMed Central  Google Scholar 

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020.https://doi.org/10.1038/s41467-020-17670-y

Article  PubMed  PubMed Central  Google Scholar 

Basudan AM. The role of immune checkpoint inhibitors in cancer therapy. Clin Pract. 2023.

Uscanga-Palomeque AC, Chávez-Escamilla AK, Alvizo-Báez CA, Saavedra-Alonso S, Terrazas-Armendáriz LD, Tamez-Guerra RS, et al. CAR-T-Cell Therapy: From the Shop to Cancer Therapy. Int J Mol Sci. 2023.https://doi.org/10.3390/ijms242115688

Article  PubMed  PubMed Central  Google Scholar 

Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review. Cells. 2023. https://doi.org/10.3390/cells12172159

Article  PubMed  PubMed Central  Google Scholar 

Qiu Y, Su M, Liu L, Tang Y, Pan Y, Sun J. Clinical application of cytokines in cancer immunotherapy. Drug Des Devel Ther. 2021.https://doi.org/10.2147/DDDT.S308578

Article  PubMed  PubMed Central  Google Scholar 

Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011.https://doi.org/10.3390/cancers3043856

Article  PubMed  PubMed Central  Google Scholar 

Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Wspolczesna Onkologia. 2017;2.

Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med. 2016.https://doi.org/10.1186/s12916-016-0571-0

Article  PubMed  PubMed Central  Google Scholar 

Xabier Mielgo-Rubio EAULQCMSM. Immunotherapy in non-small cell lung cancer: update and new insights. J Clin Transl Res. 2021.

Salzer E, Attarbaschi A. The value of immunotherapy in pediatric leukemia and lymphoma. Memo - Magazine of European Medical Oncology. 2021.https://doi.org/10.1007/s12254-021-00764-8

Article  Google Scholar 

Scotté F, Ratta R, Beuzeboc P. Side effects of immunotherapy. Curr Opin Oncol. 2019;31.

Hronek J. Research is needed to better understand combination immunotherapy side effects. ONS Voice. 2020;35.

Leana Huntley TE. Understanding immunotherapy side effects. NCCN Guidlelines for Patients. 2020;

Arumugam P, Manicka Vasagam J, Jayaseelan VP. NKAP: A new m6A RNA binding protein predicts prognosis and immunotherapy response in head and neck squamous cell carcinoma. J Stomatol Oral Maxillofac Surg [Internet]. 2025;126.https://doi.org/10.1016/j.jormas.2025.102265

Article  PubMed  Google Scholar 

Fritah H, Rovelli R, Chiang CLL, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev. 2022.https://doi.org/10.1016/j.ctrv.2022.102383

Article  PubMed  Google Scholar 

Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R. Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers (Basel). 2019.https://doi.org/10.3390/cancers11111756

Article  PubMed  Google Scholar 

Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell. 2015.https://doi.org/10.1016/j.cell.2015.03.030

Article  PubMed  PubMed Central  Google Scholar 

Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022.https://doi.org/10.3389/fphar.2022.868695

Article  PubMed  PubMed Central  Google Scholar 

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T-cell basic science to clinical practice. Nat Rev Immunol. 2020. https://doi.org/10.1038/s41577-020-0306-5

Article  PubMed  PubMed Central  Google Scholar 

Gardner D, Jeffery LE, Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. American Journal of Transplantation. 2014.https://doi.org/10.1111/ajt.12834

Article  PubMed  Google Scholar 

Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research. 2011.https://doi.org/10.1158/1078-0432.CCR-11-1595

Article  PubMed  PubMed Central  Google Scholar 

Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research. 2011. https://doi.org/10.1016/j.cell.2016.08.069

Article  PubMed  PubMed Central  Google Scholar 

Du Rusquec P, Saint-Jean M, Brocard A, Peuvrel L, Khammari A, Quéreux G, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. Journal of Immunotherapy. 2014;37.https://doi.org/10.1097/CJI.0000000000000041

Article  PubMed  Google Scholar 

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008.https://doi.org/10.1146/annurev.immunol.26.021607.090331

Article  PubMed  PubMed Central  Google Scholar 

Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6.https://doi.org/10.1126/sciadv.abd2712

Article  PubMed  PubMed Central  Google Scholar 

Philips EA, Liu J, Kvalvaag A, Mørch AM, Tocheva AS, Ng C, et al. Transmembrane domain–driven PD-1 dimers mediate T-cell inhibition. Sci Immunol. 2024;9.https://doi.org/10.1126/sciimmunol.ade6256

Article  PubMed  PubMed Central  Google Scholar 

Dang TO, Ogunniyi A, Barbee MS, Drilon A. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2016;16.

Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, et al. Five-year survival outcomes with Nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227. Journal of Clinical Oncology. 2023;41.

Philips EA, Liu J, Kvalvaag A, Mørch AM, Tocheva AS, Ng C, et al. Transmembrane domain–driven PD-1 dimers mediate T-cell inhibition. Sci Immunol. 2024;9.